Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | CSF1R | P07333 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | CCNC | P24863 | 7/20 | 0.46 |
| ▸ | CDK8 | P49336 | 7/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5591912 | 0.90 | PDGFRB (0.50) | PDGFRBCSF1RKDRCCNCCDK8 | |
| SCHEMBL4495316 | 0.87 | PDGFRB (0.55) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4508946 | 0.87 | PDGFRB (0.61) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4514154 | 0.85 | KDR (0.52) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4491303 | 0.85 | CSF1R (0.65) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL5598959 | 0.85 | PDGFRB (0.52) | PDGFRBCSF1RKDRCCNCCDK8 | |
| SCHEMBL4498768 | 0.82 | PDGFRB (0.65) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4517730 | 0.81 | CSF1R (0.49) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL5598896 | 0.81 | CSF1R (0.51) | PDGFRBCSF1RKDRFLT3KCNH2 | |
| SCHEMBL4509974 | 0.80 | MET (0.53) | PDGFRBCSF1RKDRFLT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007113565-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |